In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Discovery of the first genome-wide significant risk loci for syncope and collapse

Session What's new in genetics of heart disease

Speaker Gustav Ahlberg

Congress : ESC Congress 2019

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Biology and Physiology: Genetics, Epigenetics, ncRNA
  • Session type : Advances in Science
  • FP Number : 4259

Authors : G Ahlberg (Copenhagen,DK), K Hadji-Turdeghal (Copenhagen,DK), L Andreasen (Copenhagen,DK), CM Hagen (Copenhagen,DK), J Ghouse (Copenhagen,DK), M Baekvad-Hansen (Copenhagen,DK), J Bybjerg-Grauholm (Copenhagen,DK), DM Hougaard (Copenhagen,DK), P Hedley (Copenhagen,DK), S Haunsoe (Copenhagen,DK), JH Svendsen (Copenhagen,DK), TA Jepps (Copenhagen,DK), MW Skov (Copenhagen,DK), M Christiansen (Copenhagen,DK), MS Olesen (Copenhagen,DK)

Authors:
G Ahlberg1 , K Hadji-Turdeghal1 , L Andreasen1 , CM Hagen2 , J Ghouse3 , M Baekvad-Hansen2 , J Bybjerg-Grauholm2 , DM Hougaard2 , P Hedley2 , S Haunsoe1 , JH Svendsen1 , TA Jepps3 , MW Skov1 , M Christiansen2 , MS Olesen3 , 1Rigshospitalet - Copenhagen University Hospital - Copenhagen - Denmark , 2Statens Serum Institut, Department of Congenital Disorders - Copenhagen - Denmark , 3University of Copenhagen, Biomedical Science - Copenhagen - Denmark ,

Citation:

Background: Syncope is a common condition in the general population causing frequent hospitalisation and visits to the emergency department. Family aggregation and twin studies have previously indicated that syncope and collapse has a heritable component. 

Purpose: We investigated whether common genetic variants predispose to syncope and collapse.

Methods: We used genome-wide association data on syncope and collapse for 408,961 individuals with European ancestry from the UK Biobank study. In a replication study, the Integrative Psychiatric Research Consortium (iPSYCH) cohort (n = 86,189) was used to investigate the risk of incident syncope stratified by genotype carrier status.

Results: We report on a genome-wide significant locus on chromosome 2q32.1 with the lead SNP rs12465214 (odds ratio [OR]= 1.13, 95% confidence interval [CI] = 1.10 - 1.17, P = 5.8 x 10^-15; Figure 1a). This association was replicated in the iPSYCH cohort, where homozygous carriers of the C allele conferred an increased hazard ratio (HR = 1.30, CI = 1.15 - 1.46, P = 1.68 x 10^-5; Figure 1b). LD score regression demonstrated a significant genetic correlation (rg) with coronary artery disease (rg = 0.41, P = 6.99 x 10^-15) and related phenotypes such as angina and hypertension (Figure 1c). Analyses of eQTL (P = 4 x 10^-8) and epigenetic chromatin states revealed that variation in this locus likely affects expression of the gene ZNF804A, which resides in its proximity (Figure 1d). A qPCR analysis showed that ZNF804A was mostly expressed in the brain. A lower level of ZNF804A expression was also detected in the cerebral arteries. ZNF804A was not expressed in heart tissue.

Conclusion: rs12465214 is associated with syncope and collapse. Variation in this locus likely modulates the expression of the nearby gene ZNF804A through eQTLs and chromatin interactions. ZNF804A is mainly expressed in the brain and cerebral arteries. However, the precise function of ZNF804A is unknown. Furthermore, syncope and collapse is a polygenetic trait and share a significant genetic overlap with coronary artery disease, angina and hypertension.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are